Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Nausea and Vomiting In Patients Receiving Consecutive Days of Cisplatin

This study has been terminated.
(Administratively terminated.)
Merck Sharp & Dohme Corp.
Information provided by:
Thomas Jefferson University Identifier:
First received: July 14, 2008
Last updated: August 18, 2010
Last verified: August 2010

The purpose of this study is to observe the incidence of nausea with systemic chemotherapy that includes consecutive days (more than one day)of cisplatin medication.

Metastatic Melanoma

Study Type: Observational
Study Design: Observational Model: Case-Only
Official Title: Nausea and Vomiting In Patients Receiving Consecutive Days of Cisplatin

Resource links provided by NLM:

Further study details as provided by Thomas Jefferson University:

Primary Outcome Measures:
  • Determine incidence of nausea when receiving Dartmouth regimen chemotherapy for metastatic melanoma [ Time Frame: Week of treatment ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Assess the impact of systemic chemotherapy with Dartmouth regimen on quality of life of patients [ Time Frame: week of treatment ] [ Designated as safety issue: No ]

Enrollment: 8
Study Start Date: May 2005
Study Completion Date: March 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Metastatic melanoma treatment with Dartmouth regimen

Detailed Description:

Questionnaires are completed on week of chemotherapy treatment referred to as Dartmouth regimen.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

University practice patients with metastatic melanoma


Inclusion Criteria:

  • confirmed diagnosis metastatic melanoma
  • 18 years and older
  • undergoing chemotherapy with Dartmouth regimen
  • medically stable to receive chemotherapy per physical and clinical laboratory tests

Exclusion Criteria:

  • No medical conditions that interfere with assessment of nausea and vomiting during chemotherapy
  • No cognitive disorder that impairs symptom assessment
  • No other investigational agent
  • Inability to swallow medications for nausea and vomiting
  • No gastric outlet obstruction
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00716560

United States, Pennsylvania
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States, 19107
Sponsors and Collaborators
Thomas Jefferson University
Merck Sharp & Dohme Corp.
Principal Investigator: Takami Sato, M.D.,Ph.D. Thomas Jefferson University
  More Information

Additional Information:
No publications provided

Responsible Party: Takami Sato, MD, Thomas Jefferson University Identifier: NCT00716560     History of Changes
Other Study ID Numbers: 05C.202, 2004-101, 0402005015
Study First Received: July 14, 2008
Last Updated: August 18, 2010
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Signs and Symptoms
Signs and Symptoms, Digestive processed this record on November 19, 2014